Aventis Pharma S.a.

Rhone-poulenc Rorer S.a.

Rhone-poulenc Fibres Et Polymeres S.a.

Jo&euml;l Crouzet

B&eacute;atrice Cameron

Francis Blanche

Daniel Scherman

Pierre Wils

Alain Famechon

Jean-Claude Barriere

Jean-Marc Paris

Gilles Dutruc-Rosset

Denis Thibaut

Laurent Debussche

Nathalie Bamas-Jacques

Michel Couder

V&eacute;ronique Blanc

Patrice Yeh

Emmanuelle Vigne

Dominique Petre

Olivier Favre-Bulle

C&eacute;cile Orsini

Catherine Jourdat

Lucia Ferrero

Anne-Marie Darquet

Fran&ccedil;is Blanche

Laurent Naudin

Anne-Marie Le Coq

Novel group B streptogramin-like compounds of general formula (I), and a method for preparing streptogramines by mutasynthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramins are disclosed. Novel nucleotide sequences involved in the biosynthesis of said precursors, and their uses, are also disclosed.

Streptogramins and method for preparing same by mutasynthesis

A novel topoisomerase IV, nucleotide sequences coding for said enzyme, corresponding vectors, and the use of said enzyme for screening biologically active materials.

Topoisomerase IV, corresponding nucleotide sequences and uses thereof

Enzyme combinations useful for destroying cells, particularly proliferative cells, are disclosed. In particular, a combination of the following enzymes has been found to enhance the toxicity of nucleoside analogues to proliferating cells: an enzyme that phosphorylates the non-toxic nucleoside analogue to generate a monophosphate analogue, an enzyme that phosphorylates the monophosphate analogue to generate a diphosphate analogue and an enzyme that phosphorylates the diphosphate analogue to generate a toxic triphosphate analogue. Vectors enabling the intracellular expression and transfer of the enzyme combinations, as well as their therapeutic use, particularly in anti-cancer gene therapy, are also disclosed.

Enzyme combinations for destroying proliferative cells

Double-stranded DNA molecules characterized in that they are circular and in that they essentially include one or more genes of interest.

Circular DNA expression cassettes for gene transfer

The invention discloses the preparation of DNA, in particular plasmid DNA. More particularly it concerns the production of bacterial plasmid DNA to be used in gene therapy, in the form of plasmid, minicircle supercoiled, loose or linear.

Method for producing methylated DNA

The invention provides a method for preparing streptogramins using genetically-modified microorganisms to influence the biosynthesis of at least one of the precursors of the group B streptogramins. Cultures of the genetically-modified microorganisms are supplemented with a least one precursor that is different from the streptogramin precursor whose biosynthesis is altered and the streptogramins produced are recovered.

Streptogramins for preparing same by mutasynthesis

Method for double-stranded DNA purification, by which a solution containing said DNA in a mixture with other components is passed over a support on which is covalently coupled in oligonucleotide capable of hybridizing with a specific sequence present on said DNA to form a triple helix.

Purification of a triple helix formation with an immobilized oligonucleotide

A novel method for preparing recombinant adenoviruses and the use of such adenoviruses in gene therapy are disclosed. Plasmids used in the construction of said adenoviruses are also disclosed.

Method for preparing a recombinant adenovirus genome

The present invention relates to an enzyme with amidase activity, particularly towards substrates of the oligomer type derived from PA 6.6 (formula I) and/or PA 6 (formula II), said enzyme being characterized by a ratio

Enzymes and microorganisms having amidase activity for hydrolysing polyamides

The present invention relates to a nucleic acid sequence characterized in that it is derived from the wild nucleic acid sequence coding for a thymidine kinase, said nucleic acid sequence having at least one mutation in the region corresponding to the ATP binding site and conveniently a second mutation in the N-terminal region and/or C-terminal region. It also relates to variants of the wild thymidine kinase and their use in genic therapy.

Growing community of inventors

Sceaux, France

Joël Crouzet

Growing community of inventors

Sceaux, France

Jo&euml;l Crouzet

Joël Crouzet